EP2945646A4 - Estrogen receptor inhibitors - Google Patents

Estrogen receptor inhibitors

Info

Publication number
EP2945646A4
EP2945646A4 EP14740515.3A EP14740515A EP2945646A4 EP 2945646 A4 EP2945646 A4 EP 2945646A4 EP 14740515 A EP14740515 A EP 14740515A EP 2945646 A4 EP2945646 A4 EP 2945646A4
Authority
EP
European Patent Office
Prior art keywords
estrogen receptor
receptor inhibitors
inhibitors
estrogen
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14740515.3A
Other languages
German (de)
French (fr)
Other versions
EP2945646A1 (en
Inventor
David J Shapiro
Neal D Andruska
Mathew M Cherian
Lily Mahapatra
Mao Chengjian
William Helferich
Xujuan Yang
Xiaobin Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2945646A1 publication Critical patent/EP2945646A1/en
Publication of EP2945646A4 publication Critical patent/EP2945646A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14740515.3A 2013-01-18 2014-01-21 Estrogen receptor inhibitors Ceased EP2945646A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754292P 2013-01-18 2013-01-18
PCT/US2014/012405 WO2014113820A1 (en) 2013-01-18 2014-01-21 Estrogen receptor inhibitors

Publications (2)

Publication Number Publication Date
EP2945646A1 EP2945646A1 (en) 2015-11-25
EP2945646A4 true EP2945646A4 (en) 2016-09-21

Family

ID=51210145

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14740515.3A Ceased EP2945646A4 (en) 2013-01-18 2014-01-21 Estrogen receptor inhibitors

Country Status (5)

Country Link
EP (1) EP2945646A4 (en)
AU (1) AU2014207272A1 (en)
CA (1) CA2898732A1 (en)
IL (1) IL240019A0 (en)
WO (1) WO2014113820A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107164519A (en) * 2017-06-26 2017-09-15 深圳优圣康医学检验所有限公司 A kind of primer and probe that ESR1 gene mutations are detected based on fluorescent PCR
PE20210662A1 (en) * 2018-07-03 2021-03-31 Univ Illinois ACTIVATORS OF THE RESPONSE TO DEPLOYED PROTEINS
WO2021222738A1 (en) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Compounds for estrogen receptor positive cancers
WO2022032146A1 (en) * 2020-08-07 2022-02-10 Systems Oncology, Llc Methods for inhibiting growth of era positive cancers
CN113237860A (en) * 2021-05-17 2021-08-10 丹望医疗科技(上海)有限公司 Method for detecting maximum sectional area of organoid and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053483A (en) * 1974-05-18 1977-10-11 Doctor Andreu S.A. Derivatives of 3,3-bis-(4-hydroxyphenyl)-2-indolinone and process for the preparation thereof
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022356A1 (en) * 1990-07-31 1992-02-01 David J. Shapiro Method and materials for producing proteins
AU2005214338B2 (en) * 2004-02-13 2011-11-10 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
EP2488027A4 (en) * 2009-10-09 2013-04-17 Univ Ohio State Res Found Thiazolidinedione energy restriction-mimetic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053483A (en) * 1974-05-18 1977-10-11 Doctor Andreu S.A. Derivatives of 3,3-bis-(4-hydroxyphenyl)-2-indolinone and process for the preparation thereof
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JENSEN METTE MUNK ET AL: "Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice", PLOS ONE, vol. 5, no. 9, E12965, September 2010 (2010-09-01), pages 1 - 9, XP002760518, ISSN: 1932-6203 *
NATARAJAN A ET AL: "3,3-diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 8, 9 March 2004 (2004-03-09), pages 1882 - 1885, XP002347248, ISSN: 0022-2623, DOI: 10.1021/JM0499716 *
See also references of WO2014113820A1 *
UDDIN ET AL: "Syntheses and antiproliferative evaluation of oxyphenisatin derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 17, no. 10, 27 April 2007 (2007-04-27), pages 2854 - 2857, XP022049601, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.02.060 *

Also Published As

Publication number Publication date
EP2945646A1 (en) 2015-11-25
CA2898732A1 (en) 2014-07-24
WO2014113820A1 (en) 2014-07-24
IL240019A0 (en) 2015-09-24
AU2014207272A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
HK1221826A1 (en) Coverage extension level for coverage limited device
HK1222282A1 (en) Coverage extension level for coverage limited device
HK1216531A1 (en) Novel inhibitors
EP2975600A4 (en) Fixing device
EP2988582A4 (en) Substrate-clamp device
IL240019A0 (en) Estrogen receptor inhibitors
GB201313126D0 (en) MOS-Bipolar Device
EP2947000A4 (en) Airship-mooring device
PT3051152T (en) Connection structure for woodware part
HUE037305T2 (en) Distribution device
GB201310610D0 (en) Object-handling device
GB201303718D0 (en) Device
HK1218647A1 (en) Vasopressin-2 receptor agonists -2
GB201312493D0 (en) Stopperr device
GB201307466D0 (en) Device
GB201312010D0 (en) Receptor Agonists
TWM475903U (en) Device for praying
GB201311454D0 (en) Envelope-outlining device
HK1217700A1 (en) Polymorph forms
GB201304666D0 (en) Dopamine receptor antagonist
GB201301896D0 (en) Novel Estrogen Receptor Ligands
GB201304105D0 (en) Agonist
GB201319790D0 (en) Device for framing
GB201319680D0 (en) An indirect calorimeter
GB201312359D0 (en) Device tracability

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/565 20060101ALI20160810BHEP

Ipc: A61K 31/404 20060101ALI20160810BHEP

Ipc: A61K 31/138 20060101ALI20160810BHEP

Ipc: A61K 31/4535 20060101ALI20160810BHEP

Ipc: A61K 31/337 20060101ALI20160810BHEP

Ipc: A61K 31/4196 20060101ALI20160810BHEP

Ipc: A61K 33/24 20060101ALI20160810BHEP

Ipc: A61P 35/00 20060101ALI20160810BHEP

Ipc: A61K 39/00 20060101AFI20160810BHEP

Ipc: A61K 31/5685 20060101ALI20160810BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20160823

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4535 20060101ALI20160816BHEP

Ipc: A61K 31/138 20060101ALI20160816BHEP

Ipc: A61K 33/24 20060101ALI20160816BHEP

Ipc: A61K 31/565 20060101ALI20160816BHEP

Ipc: A61K 39/00 20060101AFI20160816BHEP

Ipc: A61K 31/4196 20060101ALI20160816BHEP

Ipc: A61P 35/00 20060101ALI20160816BHEP

Ipc: A61K 31/5685 20060101ALI20160816BHEP

Ipc: A61K 31/404 20060101ALI20160816BHEP

Ipc: A61K 31/337 20060101ALI20160816BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180828

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20210702